Thrivent Financial for Lutherans Has $1.87 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Thrivent Financial for Lutherans reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 83.2% in the fourth quarter, HoldingsChannel reports. The firm owned 39,206 shares of the biopharmaceutical company’s stock after selling 193,810 shares during the period. Thrivent Financial for Lutherans’ holdings in Halozyme Therapeutics were worth $1,874,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $150,000. CreativeOne Wealth LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at about $1,035,000. Hantz Financial Services Inc. bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth about $9,260,000. Caisse DE Depot ET Placement DU Quebec acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $5,381,000. Finally, Edgestream Partners L.P. grew its stake in shares of Halozyme Therapeutics by 116.9% in the 3rd quarter. Edgestream Partners L.P. now owns 86,001 shares of the biopharmaceutical company’s stock valued at $4,923,000 after buying an additional 46,352 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on HALO. Benchmark reiterated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $63.84 on Friday. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00. The company has a market cap of $7.89 billion, a P/E ratio of 18.61, a P/E/G ratio of 0.42 and a beta of 1.32. The firm has a 50-day moving average of $59.16 and a 200-day moving average of $54.85. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. The trade was a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,697 shares of company stock valued at $1,754,451. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.